Literature DB >> 2062512

Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group.

.   

Abstract

The Early Treatment Diabetic Retinopathy Study (ETDRS) enrolled 3711 patients with mild-to-severe nonproliferative or early proliferative diabetic retinopathy in both eyes. One eye of each patient was assigned randomly to early photocoagulation and the other to deferral of photocoagulation. Follow-up examinations were scheduled at least every 4 months and photocoagulation was initiated in eyes assigned to deferral as soon as high-risk proliferative retinopathy was detected. Eyes selected for early photocoagulation received one of four different combinations of scatter (panretinal) and focal treatment. This early treatment, compared with deferral of photocoagulation, was associated with a small reduction in the incidence of severe visual loss (visual acuity less than 5/200 at two consecutive visits), but 5-year rates were low in both the early treatment and deferral groups (2.6% and 3.7%, respectively). Adverse effects of scatter photocoagulation on visual acuity and visual field also were observed. These adverse effects were most evident in the months immediately following treatment and were less in eyes assigned to less extensive scatter photocoagulation. Provided careful follow-up can be maintained, scatter photocoagulation is not recommended for eyes with mild or moderate nonproliferative diabetic retinopathy. When retinopathy is more severe, scatter photocoagulation should be considered and usually should not be delayed if the eye has reached the high-risk proliferative stage. The ETDRS results demonstrate that, for eyes with macular edema, focal photocoagulation is effective in reducing the risk of moderate visual loss but that scatter photocoagulation is not. Focal treatment also increases the chance of visual improvement, decreases the frequency of persistent macular edema, and causes only minor visual field losses. Focal treatment should be considered for eyes with macular edema that involves or threatens the center of the macula.

Entities:  

Mesh:

Year:  1991        PMID: 2062512

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  402 in total

Review 1.  Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research.

Authors:  R Donnelly; I Idris; J V Forrester
Journal:  Br J Ophthalmol       Date:  2004-01       Impact factor: 4.638

2.  The relation between visual acuity, fixation stability, and the size and location of foveal hard exudates after photocoagulation for diabetic maculopathy: a 1-year follow-up study.

Authors:  F Møller; T Bek
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-05-15       Impact factor: 3.117

3.  Diabetic retinopathy: should this patient receive laser treatment? Overview.

Authors:  E Chew
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

Review 4.  How the diabetic eye loses vision.

Authors:  Jaime A Davidson; Thomas A Ciulla; Janet B McGill; Keri A Kles; Pamela W Anderson
Journal:  Endocrine       Date:  2007-09-27       Impact factor: 3.633

Review 5.  Anti-vascular endothelial growth factor therapy for diabetic macular edema.

Authors:  David S Boyer; J Jill Hopkins; Jonathan Sorof; Jason S Ehrlich
Journal:  Ther Adv Endocrinol Metab       Date:  2013-12       Impact factor: 3.565

6.  The accuracy of digital-video retinal imaging to screen for diabetic retinopathy: an analysis of two digital-video retinal imaging systems using standard stereoscopic seven-field photography and dilated clinical examination as reference standards.

Authors:  Mary Gilbert Lawrence
Journal:  Trans Am Ophthalmol Soc       Date:  2004

7.  Correlation of a scanning laser derived oedema index and visual function following grid laser treatment for diabetic macular oedema.

Authors:  C Hudson; J G Flanagan; G S Turner; H C Chen; L B Young; D McLeod
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

Review 8.  Is ophthalmology evidence based? A clinical audit of the emergency unit of a regional eye hospital.

Authors:  T Y Y Lai; V W Y Wong; G M Leung
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

Review 9.  A review of anti-VEGF agents for proliferative diabetic retinopathy.

Authors:  P Osaadon; X J Fagan; T Lifshitz; J Levy
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

10.  Nonmydriatic fundus photography for teleophthalmology diabetic retinopathy screening in rural and urban clinics.

Authors:  Eric K Chin; Bruna V Ventura; Kai-Yin See; Joann Seibles; Susanna S Park
Journal:  Telemed J E Health       Date:  2013-11-12       Impact factor: 3.536

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.